South & Central America Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)
The South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030; it is estimated to register a CAGR of 14.3% f... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030; it is estimated to register a CAGR of 14.3% from 2022 to 2030.Rising Trend of Personalized Vaccines Fuels South & Central America Human Vaccine Adjuvants Market Precision or personalized vaccines are a growing trend in the South & Central America human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders. Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the South & Central America human vaccine adjuvants market. South & Central America Human Vaccine Adjuvants Market Overview Brazil is among the largest countries in South & Central America. According to the Brazilian Institute of Geography and Statistics (IBGE), Brazil has a unified healthcare system (SUS) that caters health services to approximately 72% of the population. SUS provides free medication and promotes national vaccination programs mostly focused on older adults and children. According to the International Trade Administration, Brazilian public laboratories and universities play a key role in research and development for diagnostic kits, drugs, and vaccines. According to the Global Burden of Disease study published in October 2020, Brazil has an increasing prevalence of various chronic and infectious diseases, such as tuberculosis, stroke, influenza, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, and diabetes. Similarly, according to the CDC, mosquito-borne diseases (chikungunya, dengue, malaria, yellow fever, and Zika) are endemic in Brazil. Thus, the application of human vaccine adjuvants will increase due to the increasing disease burden in Brazil. Rising healthcare expenditures and an increasing geriatric population are propelling the development of human vaccine adjuvants. According to the World Bank, Brazil's healthcare expenditure was 10.31% of the GDP in 2020, a significant increase from 8.91% in 2015. Additionally, the rising geriatric population in the country is at high risk for various diseases and disabilities. The OECD reported that 21.9% of the population in Brazil is expected to be 65 years and above by 2050, a significant increase from 8.9% in 2017. Thus, the increasing geriatric population, infectious disease prevalence, and health expenditure would propel the growth of Brazil's human vaccine adjuvants market in the coming years. South & Central America Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million) South & Central America Human Vaccine Adjuvants Market Segmentation The South & Central America human vaccine adjuvants market is categorized into type, application, end user, and country. Based on type, the South & Central America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022. In terms of application, the South & Central America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022. By end user, the South & Central America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022. By country, the South & Central America human vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America human vaccine adjuvants market share in 2022. Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the South & Central America human vaccine adjuvants market. Table of ContentsTABLE OF CONTENTS1. Introduction 1.1 The Insight Partners Research Report Guidance 1.2 Market Segmentation 2. Executive Summary 2.1 Key Insights 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. South & Central America Human Vaccine Adjuvants Market - Key Market Dynamics 4.1 South & Central America Human Vaccine Adjuvants Market - Key Market Dynamics 4.2 Market Drivers 4.2.1 Rising Prevalence of Chronic Diseases 4.2.2 Growing Focus on Immunization Programs 4.3 Market Restraints 4.3.1 Manufacturing Complexities and Regulatory Challenges 4.4 Market Opportunities 4.4.1 Growing Pharmaceutical Industry 4.5 Future Trends 4.5.1 Rising Trend of Personalized Vaccines 4.6 Impact of Drivers and Restraints: 5. Human Vaccine Adjuvants Market - South & Central America Market Analysis 5.1 South & Central America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030 5.2 South & Central America Human Vaccine Adjuvants Market Forecast Analysis 6. South & Central America Human Vaccine Adjuvants Market Analysis - by Type 6.1 Particulate Adjuvant 6.1.1 Overview 6.1.2 Particulate Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 6.2 Emulsion Adjuvant 6.2.1 Overview 6.2.2 Emulsion Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 6.3 Combination Adjuvant 6.3.1 Overview 6.3.2 Combination Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 6.4 Others 6.4.1 Overview 6.4.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 7. South & Central America Human Vaccine Adjuvants Market Analysis - by Application 7.1 Influenza 7.1.1 Overview 7.1.2 Influenza: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 7.2 Hepatitis 7.2.1 Overview 7.2.2 Hepatitis: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 7.3 Human papilloma virus (HPV) 7.3.1 Overview 7.3.2 Human papilloma virus (HPV): South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 7.4 Others 7.4.1 Overview 7.4.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 8. South & Central America Human Vaccine Adjuvants Market Analysis - by End User 8.1 Pharmaceutical and Biotechnology Companies 8.1.1 Overview 8.1.2 Pharmaceutical and Biotechnology Companies: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 8.2 CMOs and CROs 8.2.1 Overview 8.2.2 CMOs and CROs: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 8.3 Others 8.3.1 Overview 8.3.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 9. South & Central America Human Vaccine Adjuvants Market - Country Analysis 9.1 South & Central America 9.1.1 South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%) 9.1.1.1 Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 9.1.1.1.1 Brazil Human Vaccine Adjuvants Market Breakdown, by Type 9.1.1.1.2 Brazil Human Vaccine Adjuvants Market Breakdown, by Application 9.1.1.1.3 Brazil Human Vaccine Adjuvants Market Breakdown, by End User 9.1.1.2 Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 9.1.1.2.1 Argentina Human Vaccine Adjuvants Market Breakdown, by Type 9.1.1.2.2 Argentina Human Vaccine Adjuvants Market Breakdown, by Application 9.1.1.2.3 Argentina Human Vaccine Adjuvants Market Breakdown, by End User 9.1.1.3 Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) 9.1.1.3.1 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Type 9.1.1.3.2 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Application 9.1.1.3.3 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by End User 10. Industry Landscape 10.1 Overview 11. Company Profiles 11.1 Novartis AG 11.1.1 Key Facts 11.1.2 Business Description 11.1.3 Products and Services 11.1.4 Financial Overview 11.1.5 SWOT Analysis 11.1.6 Key Developments 11.2 CSL Ltd 11.2.1 Key Facts 11.2.2 Business Description 11.2.3 Products and Services 11.2.4 Financial Overview 11.2.5 SWOT Analysis 11.2.6 Key Developments 11.3 Seppic SA 11.3.1 Key Facts 11.3.2 Business Description 11.3.3 Products and Services 11.3.4 Financial Overview 11.3.5 SWOT Analysis 11.3.6 Key Developments 11.4 Croda International Plc 11.4.1 Key Facts 11.4.2 Business Description 11.4.3 Products and Services 11.4.4 Financial Overview 11.4.5 SWOT Analysis 11.4.6 Key Developments 11.5 Novavax Inc 11.5.1 Key Facts 11.5.2 Business Description 11.5.3 Products and Services 11.5.4 Financial Overview 11.5.5 SWOT Analysis 11.5.6 Key Developments 11.6 Phibro Animal Health Corp 11.6.1 Key Facts 11.6.2 Business Description 11.6.3 Products and Services 11.6.4 Financial Overview 11.6.5 SWOT Analysis 11.6.6 Key Developments 12. Appendix 12.1 About The Insight Partners 12.2 Glossary of Terms
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
The Insight Partners 社の最新刊レポート
本レポートと同じKEY WORD(end user)の最新刊レポート
よくあるご質問The Insight Partners社はどのような調査会社ですか?The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/08 10:26 148.90 円 163.91 円 197.75 円 |